as 10-24-2025 3:56pm EST
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 7.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.31 - $6.20 | Next Earning Date: | 11-13-2025 |
| Revenue: | $6,000 | Revenue Growth: | -14.29% |
| Revenue Growth (this year): | 5680500% | Revenue Growth (next year): | N/A |
TCRT Breaking Stock News: Dive into TCRT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
5 months ago
Simply Wall St.
7 months ago
TipRanks
a year ago
The Telegraph
a year ago
Motley Fool
a year ago
AFP
a year ago
The information presented on this page, "TCRT Alaunos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.